eculizumab
Samsung Bioepis
[]
today at 's #eha2022, we'll share new phase 3 study results for our #hematology #biosimilar. check out our latest study: #1nn0vatingaccess 
We make high quality biologic medicines more accessible, more quickly. See our community guidelines: https://t.co/VDDbzPMJvF. #InnovatingAccess